Business
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancersSEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable resid
About this update from Adaptive Biotechnologies Corporation
[{"type":"image","alt":"Adaptive Biotechnologies","displaySize":"","headline":null,"caption":"Adaptive Biotechnologies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/e5ea8b7702560ef74ea125795697d8b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DNxqJjeDqUnxtvt2OYKPew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/e5ea8b7702560ef74ea125795697d8b2","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/DNxqJjeDqUnxtvt2OYKPew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/e5ea8b7702560ef74ea125795697d8b2","width":300,"height":169}},"lazy":false},{"type":"text","content":"Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers","length":145,"tagName":"p"},{"type":"text","content":"SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm.","length":683,"tagName":"p"},{"type":"text","content":"Data at ASCO and EHA this year continue to reinforce clonoSEQ’s role in modern hematologic oncology care — as the gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Across hematologic malignancies, these studies highlight how MRD measured by clonoSEQ continues to be broadly incorporated into both research and clinical practice:","length":400,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Multiple myeloma: Highly sensitive MRD testing continues to demonstrate depth and durability of response across novel therapies, including follow-up data from the inMMyCAR trial of CAR ...